Verrica Pharmaceuticals Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for YCANTH, which is the only FDA-approved treatment for molluscum contagiosum. Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH will become fully published April 1, 2024. -codes are a type of HCPCS Level II code commonly used to designate non-orally administered drugs and other medical devices.

J-codes help determine how managed care organizations reimburse medical providers for products and services. Inaccurately reporting medical services can cause insurance complications and make it harder to get rebates. J-codes allow providers to use the same code across all payers for reimbursement.

Using a standardized code reduces the risk of billing errors and allows companies to receive pass-through payments through government-sponsored healthcare plans. YCANTH is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first product approved by the FDA to treat molluscum ?

a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children.